Evidence map›Paper›PMID 31686312›Full record

ReviewAnnals of biomedical engineering2020

Nanoparticles for Manipulation of the Developmental Wnt, Hedgehog, and Notch Signaling Pathways in Cancer.

D M Valcourt, M N Dang, J Wang, E S Day

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

D M ValcourtDepartment of Biomedical Engineering, University of Delaware, 161 Colburn Lab, Newark, DE, 19716, USA.
M N DangDepartment of Biomedical Engineering, University of Delaware, 161 Colburn Lab, Newark, DE, 19716, USA.
J WangDepartment of Biomedical Engineering, University of Delaware, 161 Colburn Lab, Newark, DE, 19716, USA.
E S DayDepartment of Biomedical Engineering, University of Delaware, 161 Colburn Lab, Newark, DE, 19716, USA. emilyday@udel.edu.ORCID http://orcid.org/0000-0002-8707-826X
University of Delaware · USDuPont (United States) · US

Funding

Maximizing the delivery and efficacy of miRNA therapeutics through nanocarrier designR35GM119659 · NIGMS · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2016 to 2020
$2.0M
Multifunctional siRNA/antibody nanocarriers to treat metastatic triple-negative breast cancerR01CA211925 · NCI · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2019 to 2023
$1.7M
NCI NIH HHS R01 CA211925NCI NIH HHS R01CA211925NIGMS NIH HHS R35 GM119659NIGMS NIH HHS R35GM119659
6 · The paper itself

Abstract

The Wnt, Hedgehog, and Notch signaling pathways play a crucial role in early development and the maintenance of adult tissues. When dysregulated, these developmental signaling pathways can drive the formation and progression of cancer by facilitating cell survival, proliferation, and stem-like behavior. While this makes these pathways promising targets for therapeutic intervention, their pharmacological inhibition has been challenging due to the substantial complexity that exists within each pathway and the complicated crosstalk that occurs between the pathways. Recently, several small molecule inhibitors, ribonucleic acid (RNA) molecules, and antagonistic antibodies have been developed that can suppress these signaling pathways in vitro, but many of them face systemic delivery challenges. Nanoparticle-based delivery vehicles can overcome these challenges to enhance the performance and anti-cancer effects of these therapeutic molecules. This review summarizes the mechanisms by which the Wnt, Hedgehog, and Notch signaling pathways contribute to cancer growth, and discusses various nanoparticle formulations that have been developed to deliver small molecules, RNAs, and antibodies to cancer cells to inhibit these signaling pathways and halt tumor progression. This review also outlines some of the challenges that these nanocarriers must overcome to achieve therapeutic efficacy and clinical translation.

Indexed as

Drug Delivery SystemsNanoparticlesHedgehog ProteinsHumansNanomedicineNeoplasmsReceptors, NotchSignal TransductionWnt Signaling PathwayHedgehog ProteinsReceptors, NotchAntibodyDrug deliveryGene regulationMultivalencyNanocarrierNanomedicineRNA interferenceSmall molecule

Identifiers

PMID31686312
PMCPMC7196499
OpenAlexW2988451710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.